

Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab

Hagström, Emil; Steg, P. Gabriel; Szarek, Michael; Bhatt, Deepak L.; Bittner, Vera A.; Danchin, Nicolas; Diaz, Rafael; Goodman, Shaun G.; Harrington, Robert A.; Jukema, J. Wouter; Liberopoulos, Evangelos; Marx, Nikolaus; **Viigimaa, Margus** Circulation 2022 / p. 657 - 672 <https://doi.org/10.1161/CIRCULATIONAHA.121.057807> [Journal metrics at Scopus](#) [Article at Scopus](#) [Journal metrics at WOS](#) [Article at WOS](#)

Darapladib for preventing ischemic events in stable coronary heart disease

White, Harvey D.; Held, Claes; Stewart, Ralph; Tarka, Elizabeth; Brown, Rebekkah; Davies, Richard Y.; Budaj, Andrzej; Harrington, Robert A.; Steg, P. Gabriel; **Viigimaa, Margus** New England journal of medicine 2014 / p. 1702-1711
<https://doi.org/10.1056/NEJMoa1315878> [Journal metrics at Scopus](#) [Article at Scopus](#) [Journal metrics at WOS](#) [Article at WOS](#)

Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease

Wallentin, Lars; Held, Claes; Armstrong, Paul W.; Cannon, Christopher Paul; Davies, Richard Y.; Granger, Christopher B.; Hagström, Emil; Harrington, Robert A.; **Viigimaa, Margus** Journal of the American Heart Association 2016 / art. e003407
<https://doi.org/10.1161/JAHA.116.003407> [Journal metrics at Scopus](#) [Article at Scopus](#) [Journal metrics at WOS](#) [Article at WOS](#)